Latest & greatest articles for dabigatran

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dabigatran or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on dabigatran and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for dabigatran

81. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. (Abstract)

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of 2·0-3·0. In the Randomised Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial, dabigatran versus warfarin reduced both stroke and haemorrhage. We aimed (...) to investigate the primary and secondary outcomes of the RE-LY trial in relation to each centre's mean TTR (cTTR) in the warfarin population.In the RE-LY trial, 18 113 patients at 951 sites were randomly assigned to 110 mg or 150 mg dabigatran twice daily versus warfarin dose adjusted to INR 2·0-3·0. Median follow-up was 2·0 years. For 18 024 patients at 906 sites, the cTTR was estimated by averaging TTR for individual warfarin-treated patients calculated by the Rosendaal method. We compared the outcomes

2010 Lancet Controlled trial quality: predicted high

82. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Full Text available with Trip Pro

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged (...) compared oral dabigatran etexilate with subcutaneous enoxaparin, for patients undergoing total knee or hip replacement, who were over 75 years old or had moderate renal impairment. The authors concluded that dabigatran etexilate was superior to enoxaparin because it produced cost savings, with comparable efficacy and safety. The reporting was variable, but the analysis tends to support the authors' conclusions, based on the evidence available. Type of economic evaluation Cost-effectiveness analysis

2010 NHS Economic Evaluation Database.

83. Dabigatran etexilate - Venous thromboembolism prevention

Dabigatran etexilate - Venous thromboembolism prevention Common Drug Review CEDAC Meeting – November 19, 2008, CEDAC Reconsideration – January 21, 2009 Page 1 of 3 Notice of CEDAC Final Recommendation – January 28, 2009 © 2009 CADTH CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION DABIGATRAN ETEXILATE (Pradax ® – Boehringer Ingelheim Canada Ltd.) Description: Dabigatran, administered as dabigatran etexilate, is an oral antithrombotic agent. It is a reversible direct (...) thrombin inhibitor indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery. Dosage Forms: Supplied as 75 mg and 110 mg capsules. The recommended initial dose is 110 mg given one to four hours after surgery, followed by 220 mg once daily thereafter. Recommendation: The Committee recommends that dabigatran not be listed. Reasons for the Recommendation: 1. Non-inferiority compared

2009 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

84. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement Home - Monash Health Find a Location Latest news Victorian Minister for Health Jenny Mikakos MP meets a patient and researcher leading the world-first safety trial examining stem cells as therapy for acute stroke. Your health Heat kills more people than any natural disaster. Be prepared and survive the heat this summer. Our children’s hospital Monash Children’s Hospital is one of Australia’s

2009 Monash Health Evidence Reviews

85. Dabigatran versus warfarin in patients with atrial fibrillation. Full Text available with Trip Pro

Dabigatran versus warfarin in patients with atrial fibrillation. Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted (...) -dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism.Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P

2009 NEJM Controlled trial quality: predicted high

86. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Full Text available with Trip Pro

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism.In a randomized, double-blind, noninferiority trial involving patients with acute venous thromboembolism who were initially given parenteral anticoagulation therapy for a median of 9 days (interquartile range, 8 to 11), we compared oral (...) dabigatran, administered at a dose of 150 mg twice daily, with warfarin that was dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The primary outcome was the 6-month incidence of recurrent symptomatic, objectively confirmed venous thromboembolism and related deaths. Safety end points included bleeding events, acute coronary syndromes, other adverse events, and results of liver-function tests.A total of 30 of the 1274 patients randomly assigned to receive dabigatran (2.4

2009 NEJM Controlled trial quality: predicted high

87. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety

Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative (...) clinical-effectiveness and safety Ndegwa S, Moulton K, Argaez C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Ndegwa S, Moulton K, Argaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety . Ottawa: Canadian Agency

2009 Health Technology Assessment (HTA) Database.

88. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Wolowacz S E, Roskell N S, Maciver F, Beard S M, Robinson P A, Plumb J M, Dolan G, Brenkel I J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of oral dabigatran etexilate (DE) versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement

2009 NHS Economic Evaluation Database.

89. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium (...) , dabigatran etexilate, and enoxaparin sodium, for the primary prevention of venous thromboembolism in patients undergoing elective total hip or knee replacement. Rivaroxaban was less costly and more effective than dabigatran and enoxaparin, following either hip or knee replacement, but the probabilistic analysis showed uncertainty in rivaroxaban being more cost-effective than dabigatran etexilate, when both were compared with enoxaparin. Methodologically, the study was well conducted and the authors

2009 NHS Economic Evaluation Database.

90. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157) Overview | Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults | Guidance | NICE Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults Technology appraisal guidance [TA157] Published date: 24 September 2008 Share Guidance on dabigatran etexilate (Pradaxa

2008 National Institute for Health and Clinical Excellence - Technology Appraisals

91. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. (Abstract)

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. After hip replacement surgery, prophylaxis following discharge from hospital is recommended to reduce the risk of venous thromboembolism. Our aim was to assess the oral, direct thrombin inhibitor dabigatran etexilate for such prophylaxis.In this double-blind study, we randomised 3494 patients undergoing total hip replacement to treatment (...) for 28-35 days with dabigatran etexilate 220 mg (n=1157) or 150 mg (1174) once daily, starting with a half-dose 1-4 h after surgery, or subcutaneous enoxaparin 40 mg once daily (1162), starting the evening before surgery. The primary efficacy outcome was the composite of total venous thromboembolism (venographic or symptomatic) and death from all causes during treatment. On the basis of the absolute difference in rates of venous thromboembolism with enoxaparin versus placebo, the non-inferiority

2007 Lancet Controlled trial quality: predicted high

92. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing

Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of dabigatran etexilate for primary deep vein thrombosis prevention post hip and knee surgery. Timeliness warning Available on request from NHSC. Final

2006 Health Technology Assessment (HTA) Database.